Aster DM Quality Care delivered exceptional financial results for Q2 FY27, with consolidated net profit surging to ₹262 crore compared to ₹110 crore in the corresponding quarter last year. According to reports from CNBC TV18 and Business Standard, the company's revenue rose significantly to ₹2,829 crore from ₹1,197 crore in the year-ago period. The company's EBITDA increased substantially to ₹664 crore in Q2 FY27, compared with ₹250 crore a year earlier, while EBITDA margin improved to 23.5% from 20.9% in the corresponding quarter of the previous financial year. As per Business Standard, normalised PAT grew 34% to ₹281 crore, translating into a PAT margin of 10%.
The company's strong performance was supported by 12% year-on-year growth in total patient volumes during the quarter, with the company serving 2.2 million patients as reported by Business Standard. According to Business Standard, occupancy improved by 335 basis points to 68%, reflecting improved utilisation across the network. The improvement in EBITDA margin was driven by operating leverage in material and other operating costs, supported by higher patient footfall, an increase in complex procedures and a favourable payor mix. The company added 4,230 beds, taking its total bed capacity to more than 15,000, while its EBITDA growth was supported by strong performance from emerging units that recorded a rapid turnaround through improved volumes and operational efficiencies.
The company witnessed encouraging growth across complex clinical procedures during the quarter, with robotic surgeries, kidney transplants and joint replacements growing by approximately 39%, 31% and 29% respectively, as reported by Business Standard. The company also stated that medical value travel (MVT) volume grew 31% year-on-year, despite a challenging external environment. Notable clinical milestones included CARE Hospitals, HITEC City, Hyderabad, receiving Joint Commission International (JCI) accreditation, while MIMS Kasargod secured National Accreditation Board for Hospitals and Healthcare Providers (NABH) accreditation within a year of commencing operations.
The company made significant advances in clinical capabilities during the quarter, with several complex and specialised procedures performed across its network. According to Business Standard, the exchange of clinical expertise and best practices across the combined platform enabled Care Banjara in Hyderabad to perform its first adaptive deep brain stimulation procedure for Parkinson's disease management. Aster Medcity in Kochi performed Kerala's first liquid nitrogen cryoablation for breast fibroadenomas. The company also strengthened its specialised care offerings with the launch of three Centres of Excellence: the Arise Robotic Spine Institute at Aster CMI, Bengaluru; the Care Cancer Institute at Ramkrishna Care, Raipur; and the Fetal Medicine Centre of Excellence at Aster Medcity, Kochi.
Shares of Aster DM Quality Care ended 0.9% lower at ₹712.9 on the BSE on Friday, as reported by Business Standard. The stock has gained 4% over the past month and risen 17.4% so far this year. Looking ahead, the company plans to expand its healthcare network, with the Aster Trivandrum project progressing towards commissioning. As per Business Standard, Azad Moopen, executive chairman, stated that the company would focus on expanding its CONGO (Cardiac Sciences, Oncology, Neurosciences, Gastroenterology and Orthopaedics) and other high-end specialties, augmenting capacity across geographies, strengthening clinical talent and improving access to quality healthcare while unlocking the potential of its combined network.
